Spots Global Cancer Trial Database for Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor
Official Title: Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor
Study ID: NCT00889525
Interventions
Study Description
Brief Summary: This study was designed to check the efficacy of a new oral medical drug treatment, namely Cabergoline, for the treatment of Cushing Disease due to pituitary adenoma. Background: Cabergoline is a Dopamine 2 receptor agonist. Corticotroph adenoma has shown to have the D2 receptor in in vitro studies.
Detailed Description:
Keywords
Eligibility
Minimum Age: 12 Years
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Seth GSMC & KEM hospital, Mumbai, Maharashtra, India
Contact Details
Name: Nalini S Shah, DM
Affiliation: Seth GSMC and KEM hospital, Mumbai
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
